{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:01:17Z","timestamp":1771866077936,"version":"3.50.1"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEG"],"DOI":"10.2147\/ceg.s16168","type":"journal-article","created":{"date-parts":[[2011,1,26]],"date-time":"2011-01-26T03:59:00Z","timestamp":1296014340000},"page":"9","source":"Crossref","is-referenced-by-count":2,"title":["Infliximab therapy for moderately severe Crohn’s disease and ulcerative colitis: a retrospective comparison over 6 years"],"prefix":"10.2147","author":[{"given":"Andrew","family":"Szilagyi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2011,1]]},"container-title":["Clinical and Experimental Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=8635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T21:59:56Z","timestamp":1477864796000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/infliximab-therapy-for-moderately-severe-crohnrsquos-disease-and-ulcer-peer-reviewed-article-CEG"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/ceg.s16168","relation":{},"ISSN":["1178-7023"],"issn-type":[{"value":"1178-7023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}